AMLo Biosciences is a UK-based company formed in late 2017

We are dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow up care, while those identified at risk of metastasis are enabled to receive timely treatment.

The test under development will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery and development and the building of biotech companies.

Meet the AMLo team

Dr. Marie Labus
CHIEF EXECUTIVE OFFICER

Dr Marie Labus has over 16 years business experience including managing a spin-out company. In that time she has also undertaken leading roles in research strategy development, change management and various business development activities. Marie has significant experience in facilitating, developing and supporting a large and diverse portfolio of enterprise-related activities including protecting intellectual assets, project management, knowledge transfer, consultancy, CPD, patents, licensing, commercial services and Research and Development activities with the aim of commercialisation of research findings for patient benefit.

Dr. Marie Labus
CHIEF EXECUTIVE OFFICER

Dr Marie Labus has over 16 years business experience including managing a spin-out company. In that time she has also undertaken leading roles in research strategy development, change management and various business development activities. Marie has significant experience in facilitating, developing and supporting a large and diverse portfolio of enterprise-related activities including protecting intellectual assets, project management, knowledge transfer, consultancy, CPD, patents, licensing, commercial services and Research and Development activities with the aim of commercialisation of research findings for patient benefit.

Professor Penny Lovat
CHIEF SCIENTIFIC OFFICER

Professor Penny Lovat has over 30 years experience in translational medical research and is internationally renowned for her work in the melanoma field in which she has contributed to the characterization of the molecular events leading to deregulated cellular signalling in both cutaneous and uveal melanoma, with particular emphasis on apoptosis and autophagy and the development of novel biomarkers, therapeutic targets and therapeutic approaches to both prevent and treat metastatic disease. Penny has published over 70 manuscripts (current h index: 30) with >8,000 citations, including several publications in leading dermatology and cancer journals as well as being the principal investigator of numerous research studies funded both nationally and internationally. Penny has also served as a committee member of The British Society of Investigative Dermatology, and as a member of several grant advisory boards including for The British Skin Foundation.

Professor Penny Lovat
CHIEF SCIENTIFIC OFFICER

Professor Penny Lovat has over 30 years experience in translational medical research and is internationally renowned for her work in the melanoma field in which she has contributed to the characterization of the molecular events leading to deregulated cellular signalling in both cutaneous and uveal melanoma, with particular emphasis on apoptosis and autophagy and the development of novel biomarkers, therapeutic targets and therapeutic approaches to both prevent and treat metastatic disease. Penny has published over 70 manuscripts (current h index: 30) with >8,000 citations, including several publications in leading dermatology and cancer journals as well as being the principal investigator of numerous research studies funded both nationally and internationally. Penny has also served as a committee member of The British Society of Investigative Dermatology, and as a member of several grant advisory boards including for The British Skin Foundation.

Dr. Rob Ellis
CHIEF MEDICAL OFFICER

Dr Rob Ellis is a Consultant Dermatologist and Honorary Clinical Senior Lecturer at Newcastle University. Dr Ellis undertook his Doctorate investigating potential biomarkers in melanoma, and since then has been actively involved in numerous clinical and scientific projects with continued focus on melanoma. He maintains active involvement in the clinical care of all types of skin cancer, as well as undertaking public skin cancer awareness campaigns. He is a member of the Westminster based Melanoma Taskforce, the Northern Cancer Alliance Skin Cancer Specialty Group, the Society of Melanoma Research, the Melanoma Focus Group and the British Association of Dermatology.

Dr. Rob Ellis
CHIEF MEDICAL OFFICER

Dr Rob Ellis is a Consultant Dermatologist and Honorary Clinical Senior Lecturer at Newcastle University. Dr Ellis undertook his Doctorate investigating potential biomarkers in melanoma, and since then has been actively involved in numerous clinical and scientific projects with continued focus on melanoma. He maintains active involvement in the clinical care of all types of skin cancer, as well as undertaking public skin cancer awareness campaigns. He is a member of the Westminster based Melanoma Taskforce, the Northern Cancer Alliance Skin Cancer Specialty Group, the Society of Melanoma Research, the Melanoma Focus Group and the British Association of Dermatology.

Dr. Ashleigh McConnell
RESEARCH & DEVELOPMENT MANAGER

Dr Ashleigh McConnell gained several years’ experience working in NHS laboratories before attaining her masters of research in molecular biosciences at Newcastle University. Ashleigh completed her doctorate investigating novel therapeutic interventions for both cutaneous and uveal melanoma, focusing on translating biological findings into novel therapeutic approaches. Since then she has focused on commercialising research findings for patient benefit by participating in the ICURe Innovation-to-Commercialisation programme as entrepreneurial lead. In her current role, she is responsible for all aspects of laboratory research as well as company developmental activities.

Dr. Ashleigh McConnell
RESEARCH & DEVELOPMENT MANAGER

Dr Ashleigh McConnell gained several years’ experience working in NHS laboratories before attaining her masters of research in molecular biosciences at Newcastle University. Ashleigh completed her doctorate investigating novel therapeutic interventions for both cutaneous and uveal melanoma, focusing on translating biological findings into novel therapeutic approaches. Since then she has focused on commercialising research findings for patient benefit by participating in the ICURe Innovation-to-Commercialisation programme as entrepreneurial lead. In her current role, she is responsible for all aspects of laboratory research as well as company developmental activities.

AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534

Trading address: Newcastle University, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom

Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom

VAT # 285288950

Sign up for our newsletter